Objective
Age-related macular degeneration (AMD) is the world’s most important age-related blinding disorder. The current proposal utilises epidemiological data describing clinical phenotype, molecular genetics, lifestyle, nutrition, and in-depth retinal imaging derived from existing longitudinal European epidemiological cohorts and biobanks to provide three major insights needed for long-lasting prevention and therapy for AMD: (a) the development of robust algorithms utilising genetic and non-genetic risk factors to identify personalised risks of developing advanced wet and dry AMD; (b) the identification of novel biomarkers for further stratification of disease risks.
New insights from (a)+(b) will be used to elaborate preventive medical recommendations for highrisk subgroups of AMD patients; and (c) the identification of molecular drivers/biological pathways relevant for onset and progression of advanced AMD that will be used to identify and validate new therapeutic targets.
Key deliverables are:
1. Determination of AMD frequency in Europe, and assessment of AMD risk for phenotypical, genetic, environmental, and biochemical risk factors and their interaction. (WP1-3)
2. Development of a web-based prediction model for personalised risk assessment of AMD based on integration of risk profiles derived from retinal imaging, molecular genetics, assessment of lifestyle, and biochemical testing. (WP4)
3. Modelling and functional characterisation of pathophysiological pathways identified from integrated analysis of current knowledge and the above risk profiles. (WP5)
4. Experimental testing and interpretation of pathophysiological consequences of risks at the molecular level. (WP6)
5. An extension and refinement of the prediction model (WP4) based on work in WP5 and WP6 to generate clinical guidelines for the medical management of high-risk subgroups of patients with AMD. (WP7)
6. Promotion and dissemination of newly gained knowledge towards AMD prevention and therapy development
Fields of science
- medical and health scienceshealth sciencespublic healthepidemiology
- medical and health sciencesclinical medicineophthalmology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health scienceshealth sciencesnutrition
- medical and health sciencesbasic medicinephysiologyhomeostasis
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
72074 Tuebingen
Germany
See on map
Participants (14)
3015 GD Rotterdam
See on map
08003 Barcelona
See on map
6525 XZ Nijmegen
See on map
33000 Bordeaux
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75654 Paris
See on map
WC1E 6BT London
See on map
08022 BARCELONA
See on map
52074 Aachen
See on map
50829 Cologne
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4070 Basel
See on map
Participation ended
EC1V 2PD London
See on map
41092 Sevilla
See on map
BT7 1NN Belfast
See on map
4 Dublin
See on map